imatinib mesylate造句

• The solid form of imatinib mesylate in Gleevec is beta crystalline.
• The patent application claimed the final form of Gleevec ( the beta crystalline form of imatinib mesylate ).
• Research was required to define and optimise the process parameters to selectively prepare the beta crystalline form of imatinib mesylate.
• The results of clinical trials of the drug, also known as STI-571 or imatinib mesylate, generated excitement among cancer researchers.
• The medical team was testing imatinib mesylate, which is produced as Gleevec by Novartis Pharmaceuticals Corp . of East Hanover, New Jersey.
• Novartis manufactures such drugs as clozapine ( Clozaril ), diclofenac ( Voltaren ), carbamazepine ( Tegretol ), valsartan ( Diovan ) and imatinib mesylate ( Gleevec / Glivec ).
• As mentioned above, Novartis'patent application on the beta crystalline form of imatinib mesylate was filed in India in 1998 and put in a " mail-box " as per the TRIPS agreement.
• There was no way of predicting that the beta crystalline form of imatinib mesylate would possess the characteristics that would make it orally administrable to humans without going through the inventive steps.
• MRD detection of the t ( 9; 22 ) is considered standard of care for all patients with CML and is extremely valuable for patients being treated with imatinib mesylate ( Gleevec / Glivec ).
• On February 25, 2013, the FDA approved regorafenib in a second indication to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor ( GIST ) who have been previously treated with imatinib mesylate and sunitinib malate.
• This is the actual form of the drug sold as Gleevec / Glivec; a salt ( imatinib mesylate ) as opposed to a free base, and the beta crystalline form as opposed to the alpha or other form.
• Now, the beta crystalline form of Imatinib Mesylate being a pharmaceutical substance and moreover a polymorph of Imatinib Mesylate, it directly runs into section 3 ( d ) of the Act with the explanation appended to the provision ".
• In July 1997, Novartis filed a new patent application in Switzerland on the beta crystalline form of imatinib mesylate ( the mesylate polymorph of imatinib mesylate; a specific way that the individual molecules pack together to form a solid.
• Now, the beta crystalline form of Imatinib Mesylate being a pharmaceutical substance and moreover a polymorph of Imatinib Mesylate, it directly runs into section 3 ( d ) of the Act with the explanation appended to the provision ".
• In July 1997, Novartis filed a new patent application in Switzerland on the beta crystalline form of imatinib mesylate ( the mesylate polymorph of imatinib mesylate; a specific way that the individual molecules pack together to form a solid.
• On July 18, 1997, Novartis filed a new patent application in Switzerland on the beta crystalline form of imatinib mesylate ( the mesylate polymorph of imatinib mesylate; a specific way that the individual molecules pack together to form a solid.
• On July 18, 1997, Novartis filed a new patent application in Switzerland on the beta crystalline form of imatinib mesylate ( the mesylate polymorph of imatinib mesylate; a specific way that the individual molecules pack together to form a solid.
• Hence, the coming into being of the beta crystalline form of imatinib mesylate from the free base of imatinib was the result of an invention that involved technical advance as compared to the existing knowledge and brought into existence a new substance.
• :This first targeted cancer therapy, imatinib mesylate, or Gleevec, contributed to a major breakthrough in the treatment of Chronic Myelogenous Leukemia ( CML ), followed by its successful application to other malignant cancers by turning off the signal of the protein causing these cancers.
• In 2001 the United States Food and Drug Administration ( FDA ) approved imatinib mesylate in its beta crystalline form, sold by Novartis as Gleevec ( U . S . ) or Glivec ( Europe / Australia / Latin America ) . " Orange Book entry for Gleevec.